Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GJB2 | P29033 | 5/20 | 0.44 |
| ▸ | GBA1 | P04062 | 2/20 | 0.38 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.33 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.33 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.33 |
| ▸ | SSTR5 | P35346 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14885872 | 1.00 | GJB2 (0.44) | GJB2GBA1TNFSLC2A1SSTR1 | |
| SCHEMBL12177899 | 0.89 | GJB2 (0.42) | GJB2GBA1TNFSSTR1SSTR2 | |
| SCHEMBL14885866 | 0.89 | GJB2 (0.44) | GJB2GBA1TNFSSTR1SSTR2 | |
| SCHEMBL14885876 | 0.89 | GJB2 (0.44) | GJB2GBA1TNFSSTR1SSTR2 | |
| SCHEMBL12419813 | 0.88 | GJB2 (0.40) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL12419788 | 0.88 | GJB2 (0.40) | GJB2TNFSSTR1SSTR2SSTR4 | |
| SCHEMBL9926358 | 0.88 | GJB2 (0.50) | GJB2GBA1TNFSSTR1SSTR2 | |
| SCHEMBL9926368 | 0.88 | GJB2 (0.50) | GJB2GBA1TNFSSTR1SSTR2 | |
| SCHEMBL3345071 | 0.86 | GJB2 (0.41) | GJB2GBA1TNFSSTR1SSTR2 | |
| SCHEMBL3345069 | 0.86 | GJB2 (0.41) | GJB2GBA1TNFSSTR1SSTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170362265-A1 | METHODS FOR MODULAR SYNTHESIS OF N-GLYCANS AND ARRAYS THEREOF | ACADEMIA SINICA (TW) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362265-A1 | METHODS FOR MODULAR SYNTHESIS OF N-GLYCANS AND ARRAYS THEREOF | SIGLEC7, SIGLEC9, CD4 | GJB2 3462/4885GBA1 265/4885TNF 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.